Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedAug 16, 2026
DataAggregated Company Financials
Companies20
  • 7D-2.3%
  • 3M4.8%
  • 1Y-7.2%
  • YTD-9.5%

Over the last 7 days, the Healthcare industry has dropped 2.3%, driven by a pullback from Novo Nordisk of 3.4%. On the other hand Demant is actually up 5.4%. However, the industry is down 7.2% over the past year. As for the next few years, earnings are expected to grow by 4.2% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 16 Aug 2026DKK 1.8tDKK 469.1bDKK 137.8b23.1x12.8x3.7x
Tue, 14 Jul 2026DKK 1.9tDKK 469.3bDKK 147.2b20.9x12.7x4x
Thu, 11 Jun 2026DKK 1.7tDKK 468.9bDKK 147.1b19.6x11.4x3.6x
Sat, 09 May 2026DKK 1.7tDKK 467.5bDKK 148.5b20.8x11.5x3.6x
Mon, 06 Apr 2026DKK 1.5tDKK 447.8bDKK 130.1b17.4x11.3x3.3x
Wed, 04 Mar 2026DKK 1.5tDKK 448.2bDKK 131.1b17.5x11.1x3.2x
Fri, 30 Jan 2026DKK 2.1tDKK 453.2bDKK 136.7b17.5x15.6x4.7x
Sun, 28 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Tue, 25 Nov 2025DKK 1.8tDKK 454.3bDKK 137.1b17.4x13x3.9x
Thu, 23 Oct 2025DKK 2.0tDKK 447.8bDKK 141.8b18.9x14.4x4.5x
Sat, 20 Sep 2025DKK 2.2tDKK 447.3bDKK 141.7b19x15.7x5x
Mon, 18 Aug 2025DKK 1.9tDKK 444.4bDKK 140.2b28.1x13.6x4.3x
Wed, 16 Jul 2025DKK 2.4tDKK 423.3bDKK 124.5b29.9x19.1x5.6x
Fri, 13 Jun 2025DKK 2.8tDKK 423.4bDKK 124.6b31.2x22.4x6.6x
Sun, 11 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Tue, 08 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b21.9x19.5x5.8x
Thu, 06 Mar 2025DKK 3.3tDKK 409.9bDKK 121.4b27.7x27.4x8.1x
Sat, 01 Feb 2025DKK 3.3tDKK 387.7bDKK 111.4b28.8x29.2x8.4x
Mon, 30 Dec 2024DKK 3.4tDKK 387.4bDKK 111.3b29.9x30.1x8.7x
Wed, 27 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x35.2x10.1x
Fri, 25 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b33.7x38x10.9x
Sun, 22 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Tue, 20 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.4x43.8x12.6x
Thu, 18 Jul 2024DKK 4.7tDKK 355.2bDKK 106.2b35.3x43.8x13.1x
Sat, 15 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b35.5x46.7x14x
Mon, 13 May 2024DKK 4.5tDKK 354.9bDKK 106.0b34.6x42.5x12.7x
Wed, 10 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b37.3x44.2x12.9x
Fri, 08 Mar 2024DKK 4.7tDKK 341.1bDKK 99.6b38.9x47.3x13.8x
Sun, 04 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Tue, 02 Jan 2024DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Thu, 30 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33x39.9x11.2x
Sat, 28 Oct 2023DKK 3.4tDKK 305.6bDKK 82.3b26.6x41.5x11.2x
Mon, 25 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.8x41.3x11.1x
Wed, 23 Aug 2023DKK 3.4tDKK 303.7bDKK 81.3b38.4x41.4x11.1x
Price to Earnings Ratio

41.4x


Total Market Cap: DKK 3.4tTotal Earnings: DKK 81.3bTotal Revenue: DKK 303.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 28.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.8x which is lower than its 3-year average PE of 28.2x.
  • The 3-year average PS ratio of 8.2x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 19% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.48%
Healthcare-2.31%
Healthcare Services6.79%
Life Sciences5.41%
Medical Equipment1.15%
Biotech1.11%
Healthtech-0.50%
Pharma-3.22%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.8x.
    • Analysts are expecting annual earnings growth of 21.0%, which is higher than its past year's earnings growth of 9.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 8.3% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DEMANT DemantDKK 297.405.4%
+DKK 3.2b		20.6%PE25.9x
GMAB GenmabDKK 2.03k1.4%
+DKK 1.7b		35.4%PE23.8x
HLUN B H. LundbeckDKK 42.522.3%
+DKK 931.8m		8.9%PE11.3x
AMBU B AmbuDKK 76.554.3%
+DKK 831.1m		-16.7%PE42.3x
BAVA Bavarian NordicDKK 185.905.4%
+DKK 725.3m		-21.7%PE12.1x

Latest News

DEMANT
DKK 297.40
Demant
7D
5.4%
1Y
20.6%
ALK B
DKK 218.60
ALK-Abelló
7D
-2.4%
1Y
19.5%
AMBU B
DKK 76.55
Ambu
7D
4.3%
1Y
-16.7%
Narrative Update • Aug 15

AMBU B: Rising Competitive Pressure Will Drive More Cautious Share Performance

Analysts have raised their fair value estimate for Ambu to DKK 61 from DKK 58, while also reflecting slightly different assumptions for growth, margins and future P/E following recent research that highlights rising competitive pressure and a more cautious near term outlook. What’s in the News for Ambu Analysts revised their fair value estimate for Ambu to DKK 61 from DKK 58, reflecting updated assumptions on growth, margins and future P/E.
ZEAL
DKK 321.20
Zealand Pharma
7D
-3.0%
1Y
-13.4%
PEG
DKK 0.082
Pharma Equity Group
7D
-10.1%
1Y
-40.9%
BAVA
DKK 185.90
Bavarian Nordic
7D
5.4%
1Y
-21.7%
CHEMM
DKK 463.20
ChemoMetec
7D
7.7%
1Y
-7.5%
NOVO B
DKK 294.70
Novo Nordisk
7D
-3.4%
1Y
-9.6%
Narrative Update • Aug 10

NOVO: From Hypergrowth to Execution Mode

10.08.2026 New CEO Mike Doustdar: His strength lies less in building factories and more in building markets. From my perspective, the share price has been driven by a lot of exaggeration.
GMAB
DKK 2,027.00
Genmab
7D
1.4%
1Y
35.4%
Analysis Article • Aug 09

Genmab A/S Just Beat EPS By 29%: Here's What Analysts Think Will Happen Next

It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...
GUBRA
DKK 371.80
Gubra
7D
2.5%
1Y
5.3%
HLUN B
DKK 42.52
H. Lundbeck
7D
2.3%
1Y
8.9%
EMBLA
DKK 29.85
Embla Medical hf
7D
1.7%
1Y
-3.1%
Analysis Article • Jul 24

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
COLO B
DKK 428.30
Coloplast
7D
-2.1%
1Y
-29.0%
Narrative Update • Jul 15

COLO B: Recent P/E Reset Will Create Upside Opportunity

Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.
MONSO
DKK 0.24
Monsenso
7D
-13.7%
1Y
5.3%
NNIT
DKK 38.25
NNIT
7D
-0.1%
1Y
-39.1%
STENO
DKK 0.93
Stenocare
7D
-0.2%
1Y
34.8%